-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2170 Clinician Adherence to Screening and Preventive Practices for Non-Malignant Late Effects Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States

Program: Oral and Poster Abstracts
Session: 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster I
Hematology Disease Topics & Pathways:
Clinical Practice (Health Services and Quality), Study Population, Human
Saturday, December 7, 2024, 5:30 PM-7:30 PM

Catherine J. Lee, MD, MSc1, Elizabeth M Hellewell, BS1*, Kevin Ng, M.S.1*, Ted Gooley, PhD2*, Anthony D. Sung, MD3, Allison O. Taylor, MD, MS4*, Sanghee Hong, MD5*, Nausheen Ahmed, MD6*, Cherie Morey, MD7*, Sarah Fitzmaurice7*, Vanessa E. Kennedy, MD8, Michelle Lauer9*, Andrew D. Trunk, MD10, Betty K. Hamilton, MD11, Akshay Sharma, MBBS12, Zoey Phelps-Bergeron12*, LaQuisa Hill, MD13*, Rawan Faramand, MD14, Hien Liu, MD15, Lena E Winestone, MD16, Geoffrey Cheng16, Manuel Espinoza-Gutarra, MD17, Omer Jamy, MD18, Maria Odstrcil Bobillo, MD19*, Brian McClune, DO19, Mariam T. Nawas, MD20, Samuel J. Yates, MD, MSc21, Miki Nishitani, MD, BS22, Takuto Takahashi, MD, PhD22*, Jane Koo, MD23*, Kasiani C Myers, MD24, Kris Michael Mahadeo, MD25, Andrea Bauchat, DO26*, Laurie K Pearson, MD27, Ritika Walia, MD28*, Kelsea Seago, PharmD, RPh29*, Spencer Yingling, PharmD30*, Cory Edgar, PA-C31*, Amy Browning, APRN31* and Neel Bhatt, MBBS1*

1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA
2Fred Hutchinson Cancer Center, Seattle, WA
3Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, NC
4Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC
5Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC
6Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS
7Division of hematologic malignancies and cellular therapeutics, University of Kansas Cancer Center, Westwood, KS
8Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Palo Alto, CA
9Stanford University, Stanford, CA
10Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Shaker Heights, OH
11Cleveland Clinic Foundation, Cleveland, OH
12Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children’s Research Hospital, Memphis, TN
13Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Methodist Hospital, Houston, TX
14Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL
15Moffitt Cancer Center, Tampa, FL
16Division of Allergy, Immunology, & BMT, Department of Pediatrics, UCSF Benioff Children's Hospitals, San Francisco, CA
17O'Neal Comprehensive Cancer Center at University of Alabama Birmingham, Birmingham, AL
18O'Neal Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, AL
19Huntsman Cancer Institute, University of Utah, Division of Hematology and Hematologic Malignancies, Salt Lake City, UT
20Department of Medicine, Section of Hematology/Oncology, University of Chicago, Oak Park, IL
21Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL
22Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, MA
23Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
24Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
25Pediatric Transplant and Cellular Therapy, Duke University, Durham, NC
26Pediatric Transplantation and Cellular Therapy, Duke University, Durham, NC
27UMass Memorial Medical Center, Department of Medicine, Waltham, MA
28UMass Memorial Medical Center, Department of Medicine, Worcester, MA
29West Virginia University Medicine, Morgantown, WV
30West Virginia University Medicine, Morgantown
31AdventHealth, Orlando, FL

Background: Survivors of allogeneic hematopoietic cell transplantation (HCT) are at risk for treatment-related late effects. Published recommendations for screening/prevention of late complications have been available (Majhail, BBMT 2012); however, their utilization by clinicians practicing at U.S. transplant centers (TC) is unknown. We established the Real-World Assessment of Long-term Follow up in HCT (REAL-HCT) collaboration to examine clinician adherence to key screening/preventive practices across U.S. TC. We report our findings related to non-malignant late effects (NMLEs).

Methods: This retrospective study included pts of any age who received first or greater HCT for a hematologic malignancy between January 1, 2016 to December 31, 2016, with any conditioning regimen, donor/graft, and were alive and disease-free at ≥3 yrs post HCT. Prior autologous HCT or CAR-T was allowed but not receipt of a subsequent HCT for graft failure within 3 yrs post HCT. Patient, disease and transplant characteristics, and tests related to bone health/endocrine, metabolic and renal systems, and dental health were abstracted from EMR. “Adherence” to a specific screening test was defined by evidence of a clinician order or test completion between 1-3 yrs post HCT. Two separate multivariable logistic regression models were created to assess the factors associated with NMLEs screening. Model 1 included a best subset of pt and HCT factors [age, sex, race, ethnicity, highest education, preferred language, disease diagnosis, HCT-CI score, conditioning intensity, TBI use, history of aGVHD and/or cGVHD, high-dose corticosteroid (CS) exposure, and primary post HCT survivorship provider (SP)]. Model 2 consisted of TC factors: center type (academic vs. non-academic), TC annual volume, availability of an LTFU/survivorship clinic (L/SC), and provision of a survivorship care plan (SCP) to pt, referring heme/onc provider (HOP) or PCP.

Results: The population included 440 pts [≥ 18 yrs (n=355); <18 yrs (n=85)] from 19 TC. The median age was 46 yrs (range, 0-77), 58% were male, 82% were White, 12% were Hispanic/Latino ethnicity, and English (88%) was the preferred language. The most common HCT indications were AML (43%) and ALL (22%), and a myeloablative regimen and TBI was used for 71% and 42% of pts, respectively. Approximately half of the pts had HCT-CI score <3 (49%), aGVHD (57%) and/or cGVHD (53%) or received CS (51%). The primary HCT team (68%) and PCP (59%) were reported as the most common post HCT SP. Among 19 TC, less than half reported having an L/SC (47%), SCP routinely given to the pt (32%), referring HOP (37%) or PCP (47%) during 2016-2019.

Clinician adherence to NMLE screening practices were as follows: DEXA 44%, vitamin D level 67%, HbA1c 39%, fasting glucose 38%, lipid panel 67%, thyroid test 72%, renal test 71%, and dental exam 56%. Increasing patient age [OR 1.03, 95% CI 1.02-1.05, p<0.001], non-White race [3.24, 1.57-6.67, p=0.001], TBI [2.66, 1.52-4.68, p<0.001], and cGVHD [3.29, 1.89-5.73, p<0.001] were associated with increased DEXA screening while a non-myeloablative (NMA) regimen [0.38, 0.19-0.76, p=0.006] was associated with less adherence to DEXA testing. Only TBI was predictive for an increase in adherence to vitamin D testing [2.50, 1.45-4.31, p<0.001]. An NMA regimen [2.53, 1.44-4.48, p=0.001] and cGVHD [1.91, 1.17-3.11, p=0.01] were associated with HbA1c testing, and increasing age [1.02, 1.01-1.03, p=0.01] for fasting glucose screening. TBI and cGVHD were associated with increased adherence to lipid [TBI: 1.82, 1.08-3.05, p=0.02; cGVHD: 1.87, 1.15-3.03, p=0.01] and renal [TBI: 2.44, 1.37-4.35, p=0.002; cGVHD: 1.93, 1.06-3.52, p=0.03] testing. Provision of a SCP to pt was associated with less adherence to DEXA testing [0.52, 0.31-0.88, p=0.01]. Higher annual TC volume was associated with clinician adherence to all NMLE screening tests.

Conclusion: This is the first report of clinician adherence to recommended screening/preventive guidelines for HCT survivors across 19 TC in the U.S. Less than half of pts were screened for bone density and diabetes while higher adherence to lipid, thyroid, kidney function, and oral health was observed. Several factors were associated with adherence, and these findings will guide the development of interventions to improve clinician adherence to screening/preventive practice guidelines.

Disclosures: Lee: Aptitude Health: Consultancy; SEI: Consultancy; ScientiaCME: Consultancy; Sanofi: Consultancy, Honoraria, Speakers Bureau; Incyte: Consultancy, Honoraria, Research Funding. Sung: Janssen: Consultancy; Geron: Consultancy; Novartis: Research Funding; BlueSpark Technologies: Other: Research product; Targazyme: Consultancy; Acrotech: Consultancy; Clasado: Other: Research product; Seres: Research Funding; DSM/iHealth: Other: Research product; Enterome: Research Funding; Merck: Research Funding. Hong: Guidepoint: Consultancy. Ahmed: Bristol Myers Squibb: Consultancy; Kite, a Gilead Company: Research Funding. Kennedy: Astellas: Consultancy. Hamilton: ACI group: Consultancy; Nkarta: Other: Ad hoc advisory board; Orca Bio: Research Funding; Angiocrine: Other: DSMB; Maat Pharma: Other: ad hoc advisory board; Rigel: Other: ad hoc advisory board; CSL Behring: Other: Adjudication committee; Incyte: Consultancy; Sanofi: Other: ad hoc advisory board. Sharma: BEAM therapeutics: Other: Clinical Trial site-PI; Novartis: Other: Clinical Trial site-PI; Sangamo Therapeutics: Consultancy; Editas Medicine: Consultancy; Vertex Pharmaceuticals: Consultancy, Other: Clinical Trial site-PI; Medexus Inc: Consultancy; CRISPR Therapeutics: Other: Clinical Trial site-PI and Research funding . Hill: Kite, a Gilead Company: Speakers Bureau; Gilead Sciences: Speakers Bureau; March Biosciences: Consultancy. Faramand: Novartis: Research Funding; Autolus: Membership on an entity's Board of Directors or advisory committees; Sanofi: Consultancy, Honoraria; Orca Bio: Research Funding; Kite/Gilead: Membership on an entity's Board of Directors or advisory committees. Liu: BioLineRx: Consultancy, Honoraria. Myers: Incyte: Research Funding; Elixirgen Therapeutics: Research Funding. Mahadeo: Jazz: Consultancy, Other: PI; Syndax: Other: PI; Adaptimmune: Other: PI; Vertex: Consultancy; ATARABio: Consultancy, Research Funding. Yingling: Bristol Myers Squibb: Current Employment, Current holder of stock options in a privately-held company. Edgar: Jazz Pharmaceuticals: Honoraria, Speakers Bureau; Takeda Pharmaceuticals: Honoraria, Speakers Bureau. Bhatt: Aptitude Health: Consultancy; Putnam Associates: Consultancy; Atheneum: Consultancy; Slingshot Insights: Consultancy.

*signifies non-member of ASH